Total Payments
$85,882
2024 Payments
$63,152
Companies
38
Transactions
190
Medicare Patients
15,709
Medicare Billing
$7.9M
Payment Breakdown by Category
Research$69,994 (81.5%)
Food & Beverage$5,239 (6.1%)
Consulting$4,920 (5.7%)
Travel$3,554 (4.1%)
Gifts$1,805 (2.1%)
Other$218.76 (0.3%)
Education$151.44 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $69,994 | 20 | 81.5% |
| Food and Beverage | $5,239 | 152 | 6.1% |
| Consulting Fee | $4,920 | 2 | 5.7% |
| Travel and Lodging | $3,554 | 3 | 4.1% |
| Gift | $1,805 | 2 | 2.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $207.52 | 8 | 0.2% |
| Education | $151.44 | 2 | 0.2% |
| Honoraria | $11.24 | 1 | 0.0% |
Payments by Type
Research
$69,994
20 transactions
General
$15,888
170 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Alimera Sciences, Inc. | $62,604 | 27 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $7,752 | 12 | $0 (2021) |
| Regeneron Healthcare Solutions, Inc. | $6,890 | 14 | $0 (2024) |
| Roche TCRC, Inc. | $2,437 | 2 | $0 (2019) |
| Carl Zeiss Meditec, Inc. | $1,786 | 1 | $0 (2017) |
| Genentech USA, Inc. | $663.58 | 18 | $0 (2024) |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $458.56 | 17 | $0 (2024) |
| Allergan, Inc. | $454.00 | 18 | $0 (2021) |
| Apellis Pharmaceuticals, Inc. | $356.68 | 7 | $0 (2024) |
| Mallinckrodt Enterprises LLC | $304.90 | 17 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $63,152 | 28 | Alimera Sciences, Inc. ($62,374) |
| 2023 | $647.26 | 12 | Coherus Biosciences Inc. ($195.05) |
| 2022 | $897.63 | 14 | Genentech USA, Inc. ($303.01) |
| 2021 | $1,477 | 9 | Regeneron Pharmaceuticals, Inc. ($1,339) |
| 2020 | $567.22 | 14 | Allergan, Inc. ($180.59) |
| 2019 | $5,654 | 33 | Regeneron Pharmaceuticals, Inc. ($2,721) |
| 2018 | $10,804 | 44 | Regeneron Healthcare Solutions, Inc. ($6,376) |
| 2017 | $2,684 | 36 | Carl Zeiss Meditec, Inc. ($1,786) |
All Payment Transactions
190 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/05/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $21.99 | General |
| Category: Ophthalmology | ||||||
| 12/05/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $19.00 | General |
| Category: EYE CARE | ||||||
| 10/30/2024 | Tarsus Pharmaceuticals, Inc. | XDEMVY (Drug) | Food and Beverage | In-kind items and services | $108.05 | General |
| Category: DEMODEX BLEPHARITIS | ||||||
| 10/24/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $18.13 | General |
| Category: Ophthalmology | ||||||
| 10/20/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $32.14 | General |
| Category: Immunology and Ophthalmology | ||||||
| 10/18/2024 | Ocular Therapeutix, Inc. | DEXTENZA (Drug) | Food and Beverage | In-kind items and services | $36.15 | General |
| Category: Corticosteroid intracanalicular insert | ||||||
| 10/16/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $20.48 | General |
| Category: Ophthalmology | ||||||
| 09/28/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $134.21 | General |
| Category: OPHTHALMOLOGY | ||||||
| 09/26/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $18.97 | General |
| Category: EYE CARE | ||||||
| 09/17/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $14.64 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 09/15/2024 | Alimera Sciences, Inc. | ILUVIEN (Drug) | — | Cash or cash equivalent | $2,826.00 | Research |
| Study: Iluvien Study • Category: treatment of diabetic macular edema in patients who have been previously treated with corticosteroid | ||||||
| 09/09/2024 | Heron Therapeutics, Inc. | ZYNRELEF (Drug) | Food and Beverage | In-kind items and services | $20.08 | General |
| Category: POST SURGICAL PAIN RELIEF | ||||||
| 08/01/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $19.46 | General |
| Category: EYE CARE | ||||||
| 07/25/2024 | Alimera Sciences, Inc. | ILUVIEN (Drug) | — | Cash or cash equivalent | $8,986.50 | Research |
| Study: Iluvien Study • Category: treatment of diabetic macular edema in patients who have been previously treated with corticosteroid | ||||||
| 07/17/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | Cequa (Drug) | Food and Beverage | In-kind items and services | $106.63 | General |
| Category: Ophthalmology | ||||||
| 06/04/2024 | Alimera Sciences, Inc. | ILUVIEN (Drug) | — | Cash or cash equivalent | $2,094.35 | Research |
| Study: Iluvien Study • Category: treatment of diabetic macular edema in patients who have been previously treated with corticosteroid | ||||||
| 05/29/2024 | Alimera Sciences, Inc. | ILUVIEN (Drug) | — | Cash or cash equivalent | $12,589.20 | Research |
| Study: Iluvien Study • Category: treatment of diabetic macular edema in patients who have been previously treated with corticosteroid | ||||||
| 05/03/2024 | Harrow Eye, LLC | — | Food and Beverage | In-kind items and services | $58.90 | General |
| 04/04/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $33.69 | General |
| Category: Ophthalmology | ||||||
| 03/27/2024 | Alimera Sciences, Inc. | ILUVIEN (Drug) | — | Cash or cash equivalent | $10,003.50 | Research |
| Study: Iluvien Study • Category: treatment of diabetic macular edema in patients who have been previously treated with corticosteroid | ||||||
| 03/12/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $23.23 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 03/01/2024 | Alimera Sciences, Inc. | ILUVIEN (Drug) | — | Cash or cash equivalent | $4,285.83 | Research |
| Study: Iluvien Study • Category: treatment of diabetic macular edema in patients who have been previously treated with corticosteroid | ||||||
| 02/22/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $16.94 | General |
| Category: EYE CARE | ||||||
| 02/20/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $23.15 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 02/19/2024 | Alimera Sciences, Inc. | ILUVIEN (Drug) | — | Cash or cash equivalent | $6,446.79 | Research |
| Study: Iluvien Study • Category: treatment of diabetic macular edema in patients who have been previously treated with corticosteroid | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Iluvien Study | Alimera Sciences, Inc. | $62,313 | 9 |
| A Phase 3, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients With Moderately Severe to Severe Nonproliferative Diabetic Retinopathy | Regeneron Pharmaceuticals, Inc. | $3,168 | 2 |
| A PHASE 3, DOUBLE-MASKED, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT INJECTION IN PATIENTS WITH MODERATELY SEVERE TO SEVERE NONPROLIFERATIVE DIABETIC RETINOPATHY | Regeneron Pharmaceuticals, Inc. | $3,054 | 2 |
| A Randomized, Single-Masked, Active-Controlled Phase 2 Study of the Safety, Tolerability, and Efficacy of Repeated Doses of High-Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration | Regeneron Pharmaceuticals, Inc. | $1,006 | 6 |
| EYLEA CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $453.60 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 26 | 3,129 | 28,202 | $4.6M | $1.8M |
| 2022 | 26 | 3,514 | 10,145 | $4.7M | $1.9M |
| 2021 | 24 | 3,798 | 11,478 | $5.9M | $2.5M |
| 2020 | 28 | 5,268 | 13,142 | $4.8M | $1.7M |
Total Patients
15,709
Total Services
62,967
Medicare Billing
$7.9M
Procedure Codes
104
All Medicare Procedures & Services
104 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 83 | 19,983 | $1.2M | $581,156 | 48.5% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 86 | 565 | $786,800 | $392,072 | 49.8% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2023 | 82 | 1,180 | $589,000 | $219,128 | 37.2% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 599 | 1,420 | $505,520 | $145,210 | 28.7% |
| 67028 | Injection of drug into eye | Office | 2023 | 238 | 1,077 | $518,400 | $110,792 | 21.4% |
| J3490 | Unclassified drugs | Office | 2023 | 33 | 85 | $327,350 | $97,333 | 29.7% |
| 92134 | Imaging of retina | Office | 2023 | 656 | 1,632 | $213,690 | $55,810 | 26.1% |
| J2781 | Injection, pegcetacoplan, intravitreal, 1 mg | Office | 2023 | 18 | 375 | $75,000 | $45,135 | 60.2% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 157 | 178 | $58,028 | $21,369 | 36.8% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 124 | 218 | $54,064 | $16,799 | 31.1% |
| 67041 | Removal of membrane of retina | Facility | 2023 | 16 | 17 | $44,200 | $15,845 | 35.8% |
| 92287 | Imaging of front third of eye using a special camera after injection of a dye | Office | 2023 | 85 | 90 | $34,200 | $10,598 | 31.0% |
| 67210 | Destruction of growth of retina using a laser | Office | 2023 | 15 | 20 | $24,000 | $8,661 | 36.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 52 | 70 | $20,860 | $7,848 | 37.6% |
| 67036 | Removal of eye fluid (vitreous) between lens and retina | Facility | 2023 | 12 | 13 | $26,752 | $7,189 | 26.9% |
| 92202 | Extended exam of the back part of the eye with optic nerve drawing | Office | 2023 | 378 | 567 | $47,628 | $7,021 | 14.7% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 55 | 55 | $23,430 | $6,274 | 26.8% |
| J7999 | Compounded drug, not otherwise classified | Office | 2023 | 34 | 78 | $34,850 | $5,157 | 14.8% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2023 | 196 | 222 | $18,870 | $4,291 | 22.7% |
| 92250 | Photography of the retina | Office | 2023 | 50 | 62 | $12,896 | $1,868 | 14.5% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 24 | 34 | $4,760 | $1,406 | 29.5% |
| 92083 | Exam of visual field with extended testing | Office | 2023 | 16 | 19 | $2,850 | $1,018 | 35.7% |
| 67515 | Injection of drug or substance into membrane covering eyeball | Office | 2023 | 20 | 26 | $3,850 | $952.20 | 24.7% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 66 | 86 | $1,720 | $818.72 | 47.6% |
| 92136 | Measurement of corneal curvature and depth of eye | Office | 2023 | 13 | 14 | $2,160 | $511.12 | 23.7% |
About Dr. Patrick Higgins, MD
Dr. Patrick Higgins, MD is a Ophthalmology healthcare provider based in Bloomfield, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1285642470.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Patrick Higgins, MD has received a total of $85,882 in payments from pharmaceutical and medical device companies, with $63,152 received in 2024. These payments were reported across 190 transactions from 38 companies. The most common payment nature is "" ($69,994).
As a Medicare-enrolled provider, Higgins has provided services to 15,709 Medicare beneficiaries, totaling 62,967 services with total Medicare billing of $7.9M. Data is available for 4 years (2020–2023), covering 104 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Location Bloomfield, NJ
- Active Since 08/03/2006
- Last Updated 06/09/2023
- Taxonomy Code 207W00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1285642470
Products in Payments
- ILUVIEN (Drug) $62,380
- EYLEA AFLIBERCEPT INJECTION (Biological) $10,144
- EYLEA (Biological) $4,294
- Non-Covered Product (Drug) $2,437
- CIRRUS HD-OCT (Device) $1,786
- OZURDEX (Drug) $395.45
- ACTHAR (Biological) $317.53
- VABYSMO (Drug) $303.01
- Lucentis (Biological) $297.22
- ForeseeHome (Device) $218.76
- Cimerli (Biological) $195.05
- DURYSTA (Drug) $177.55
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD) (Device) $157.51
- EYLEA HD (Biological) $134.21
- DEXTENZA (Drug) $126.95
- YUTIQ (Drug) $125.46
- BromSite (bromfenac ophthalmic solution) 0.075% (Drug) $122.14
- CEQUA (Drug) $121.36
- Iluvien (Drug) $115.04
- enVista MX60 IOL (Device) $113.51
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Bloomfield
Dr. Devang Bhoiwala, M.d, M.D
Ophthalmology — Payments: $7,440
Ophthalmology $7,440
Mitchell Vogel, M.d, M.D
Ophthalmology — Payments: $4,623
Ophthalmology $4,623
Lee Angioletti, M.d, M.D
Ophthalmology — Payments: $3,170
Ophthalmology $3,170
Dr. James Pasternack, M.d, M.D
Ophthalmology — Payments: $2,321
Ophthalmology $2,321
Joshua Gould, M.d, M.D
Ophthalmology — Payments: $2,191
Ophthalmology $2,191
Dr. Jonathan Ditkoff, M.d, M.D
Ophthalmology — Payments: $2,041
Ophthalmology $2,041